CD47 and cancer: Therefore, the targeting of CTLA-4 and PD-1 negative immune checkpoints-based immune suppression pathway along with some other important regulatory checkpoints such as Siglec factors and CD47-SIRPα may contribute to the upgrade of immune responses against cancer cells.